Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010 Nov;56(5):816-8.
doi: 10.1161/HYPERTENSIONAHA.110.154385. Epub 2010 Oct 4.

Estrogen metabolomics: a physiologist's perspective

Virginia M Miller
Editorial

Estrogen metabolomics: a physiologist's perspective

Virginia M Miller. Hypertension. 2010 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Schematic summarizing the metabolism and genomic pathways activated by 2-methoxyestradiol and their functional consequences. Abbreviations: COMT, catechol-O-methyltransferase, COX-2, cyclo-oxygenase 2; E2, 17 β estradiol; HIF-1α, hypoxia inducible factor 1α; 2-ME, 2-methoxyestradiol; MMP, matrix metalloproteinase; PPARγ, peroxisome proliferator activated receptor γ; minuses (−) negative regulation; pluses (+), positive regulations; question mark (?), unknown.
See this image and copyright information in PMC

Comment on

References

    1. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: Review and perspectives. Carcinogenesis. 1998;19:1–27. - PubMed
    1. Barchiesi F, Lucchinetti E, Zaugg M, Ogunshola OO, Wright M, Meyer M, Rosselli M, Gillespie DG, Jackson EK, Dubey RK. Candidate genes for 2-methoxyestradiol-mediated vasoprotective actions in human aortic smooth muscle cells. Hypertension. 2010;XXX:XXX. - PMC - PubMed
    1. Mooberry SL. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol. 2003;15:425–430. - PubMed
    1. Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G. A phase ii multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res. 2005;11:6625–6633. - PubMed
    1. Bourghardt J, Bergstrom G, Krettek A, Sjoberg S, Boren J, Tivesten A. The endogenous estradiol metabolite 2-methoxyestradiol reduces atherosclerotic lesion formation in female apolipoprotein e-deficient mice. Endocrinology. 2007;148:4128–4132. - PubMed